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Abstract
Background: Reliable studies of the incidence and characteristics of medical end-of-life decisions
with a certain or possible life shortening effect (ELDs) are indispensable for an evidence-based
medical and societal debate on this issue. This article presents the protocol drafted for the 2007
ELD Study in Flanders, Belgium, and outlines how the main aims and challenges of the study (i.e.
making reliable incidence estimates of end-of-life decisions, even rare ones, and describing their
characteristics; allowing comparability with past ELD studies; guaranteeing strict anonymity given
the sensitive nature of the research topic; and attaining a sufficient response rate) are addressed in
a post-mortem survey using a representative sample of death certificates.
Study design: Reliable incidence estimates are achievable by using large at random samples of
death certificates of deceased persons in Flanders (aged one year or older). This entails the
cooperation of the appropriate administrative authorities. To further ensure the reliability of the
estimates and descriptions, especially of less prevalent end-of-life decisions (e.g. euthanasia), a
stratified sample is drawn. A questionnaire is sent out to the certifying physician of each death
sampled. The questionnaire, tested thoroughly and avoiding emotionally charged terms is based
largely on questions that have been validated in previous national and European ELD studies.
Anonymity of both patient and physician is guaranteed through a rigorous procedure, involving a
lawyer as intermediary between responding physicians and researchers. To increase response we
follow the Total Design Method (TDM) with a maximum of three follow-up mailings. Also, a non-
response survey is conducted to gain insight into the reasons for lack of response.
Discussion: The protocol of the 2007 ELD Study in Flanders, Belgium, is appropriate for achieving
the objectives of the study; as past studies in Belgium, the Netherlands, and other European
countries have shown, strictly anonymous and thorough surveys among physicians using a large,
stratified, and representative death certificate sample are most suitable in nationwide studies of
incidence and characteristics of end-of-life decisions. There are however also some limitations to
the study design.
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The quality of medical care at the end of life has become
of major importance in contemporary developed societies
[1-5]. In the past century there has been a significant shift
in cause of death, away from acute deaths due to infec-
tious disease towards deaths caused by chronic and
degenerative illness such as cancer and cardiovascular dis-
ease [1-3,6]. Combined with rising life expectancy and an
ageing population, this epidemiological transition has
resulted in an increased number of people experiencing a
terminal illness phase at the end of life [1,6].
Parallel to these changes in the patterns of dying, advances
in medical knowledge and technology have contributed
considerably to the increase of treatment possibilities at
the end of life. Physicians are now increasingly able to
ensure effective treatment of pain and symptoms at the
end of life, and to postpone a patient's death [1,2,4,6].
However, in many cases a point is reached where those
involved feel that prolonging life is no longer desirable as
a certain minimal quality of life cannot always be main-
tained [1,5-8]. This gives rise to decisions that possibly or
certainly hasten the patient's death, i.e. end-of-life deci-
sions (ELDs). These decisions include withholding or
withdrawing potentially life-sustaining treatment, intensi-
fying pain and/or symptom management with a possible
life-shortening effect and administering drugs with the
explicit intention of hastening death (i.e. physician-
assisted suicide, life-ending without the patient's explicit
request, and euthanasia).
Past studies in different countries have revealed that these
various end-of-life decisions are made in a significant pro-
portion of deaths [8-20], although incidence estimates
vary somewhat across countries. According to the 2001
EURELD study in six European countries (Belgium, The
Netherlands, Denmark, Italy, Sweden and Switzerland)
the incidence of deaths preceded by an ELD ranges from
23% to 51% [14]. In Belgium the incidence rate dropped
slightly, although not statistically significantly, from
39,3% to 38,4% between 1998 and 2001 [19]. These stud-
ies contributed to an ongoing ethical and legal debate
concerning end-of-life decisions, culminating in Belgium
in 2002 with the passing of the laws on palliative care,
patients' rights and euthanasia (which permits euthanasia
under strict conditions of prudent practice) [21-24].
It is in this new legal context that a third ELD study in Bel-
gium was undertaken. This study is part of the larger Mon-
itoring quality of End-of-Life Care (MELC) study in
Flanders [25], and aims to obtain reliable incidence esti-
mates of ELDs and their characteristics in Flanders for
2007, as well as to take a closer look at the decision-mak-
ing process preceding ELDs and the treatment and care
provided at the end of life. As a third measurement point
for Flanders, one of the research aims is to permit a trend
analysis of end-of-life decision making. Furthermore, the
legalisation of euthanasia since the last ELD study in Flan-
ders creates the opportunity of estimating the possible
effects of the euthanasia law on the practice of euthanasia
and other end-of-life practices [24], and will shed light on
the argument that legalising euthanasia will possibly lead
to a slippery slope, e.g. a rise in life-ending acts without
the patient's explicit request [26,27]. Comparison of the
results of the Flemish study to the Dutch data from 2005
will put the findings in an international perspective [24].
To design an adequate methodology for a nationwide
study of ELDs is not straightforward because of the sensi-
tive nature of the issue and the specific difficulties
involved in the organisation of such a survey. In this arti-
cle we present the protocol of the 2007 Flemish ELD
study, which was guided by four methodological ques-
tions: (1) which study design is most appropriate for
obtaining reliable incidence estimates and descriptions of
ELDs, even of rare ELDs, that are representative for all
deaths in Flanders in 2007?; (2) how can comparability
with earlier ELD studies in Flanders and other countries
be ensured?; (3) how can strict anonymity of physicians
and patients for ethical and judicial reasons be guaran-
teed?; and (4) how can a sufficient response rate for a sur-
vey on this sensitive subject be achieved?
The study design we present in this article is based on a
method, first developed in the Netherlands in 1990 [9],
that has been successfully used in several European coun-
tries to study the nationwide incidence and characteristics
of ELDs [8-10,13-15,19,20]. However, this is the first time
that this study design has been described in detail. We
believe that presenting it will be useful to researchers in
other countries who intend to embark on similar research.
The methodology outlined in this article will also serve as
a reference for future publications using data from this
study.
Method design
A retrospective survey based on death certificates
Obtaining data from a representative sample of dying
patients in a prospective study design is an impossible
task, as this would entail following an excessively large
number of patients in numerous care settings. Moreover,
defining who is dying is never clear-cut, and the problems
of patient burden and attrition or non-response of the
sickest patients [28,29] rules out the option of a prospec-
tive study design. There is also a danger that a prospective
study will influence the behaviour of physicians and other
caregivers. A retrospective (post-mortem) study design
was therefore the more favourable option for this study.Page 2 of 10
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ELDs for all deaths in Flanders, it was desirable to take the
death case as the unit of measurement as this evidently
provides a clear epidemiological denominator for the
entire population of deaths, as well as for the subpopula-
tions of deaths, e.g. cancer deaths. This provides more reli-
able incidence estimates than incidence studies where the
physician is the unit of measurement and a representative
sample of physicians are asked to report on the last death
under their supervision in e.g. the last 12 months
[11,12,18]. In these studies, the number of deaths per par-
ticipating physician is often not taken into account, and
ELD incidence rates on population level are estimated on
the basis of physician characteristics. Also, recall bias can
be considerable if the physician's last death occurred a
long time before the study.
Every death in Belgium must be registered via a death cer-
tificate issued by the civil registrar of the municipality
where the death took place. The physician completes the
first part of the death certificate, indicating the sex of the
deceased, some medical information (such as causes of
death), time and place of death and signs the certificate
with full name and medical registration number. The sec-
ond part of the death certificate (containing socio-demo-
graphic information about the residence, age, education,
occupation, nationality, civil status and living situation of
the deceased) is completed by the civil registrar of the
municipality in which the death took place. The death cer-
tificates are first processed by the provinces where the
death occurred before they are sent to the central admin-
istration authorities. For Flemish death certificates this is
the Flemish Agency for Care and Health (part of the Flem-
ish Ministry for Welfare, Public Health and Family).
Death certificates are thus particularly suitable for a
nationwide study of ELDs; because every death is repre-
sented by a death certificate, it is easy to draw a represent-
ative sample of deaths. Also, the certifying physician's
identification details listed on the death certificates allow
the physician to function as the observational unit for the
study. Furthermore, the socio-demographic and morbid-
ity data of the deceased are readily available on the certif-
icates and can be included in the survey. We obtained
permission from the Flemish Agency for Care and Health
to conduct a cross-sectional postal survey among the cer-
tifying physicians of a representative sample of death cer-
tificates.
Selection of deaths and sampling
The selection of deaths and sampling procedure needed to
provide a representative sample of all deaths in Flanders
in 2007 and had to include a sufficient amount of deaths
to yield reliable information on the characteristics of all
types of ELDs. Inclusion criteria for the study were:
- the death taking place in Flanders,
- the deceased is a resident of Belgium at the time of death,
- the deceased is aged one year or more at the time of
death.
The death must have occurred in Flanders as the aim of
the study is to describe end-of-life practices in the Flemish
region; the limited number of Flemish residents who died
outside Flanders are thus not included. The criterion of
residence in Belgium is necessary to exclude all deaths in
Flanders of persons, with or without the Belgian national-
ity, who live abroad as their socio-demographic character-
istics and medical history would not be available. The
number of these deaths is very small anyway and the
majority of them are caused by traffic accidents, indicating
a low likelihood of an ELD preceding death. Deaths of
neonates (under one year of age) are excluded because
end-of-life decision making is a very different issue in this
age group, requiring an adjusted questionnaire. ELD stud-
ies in neonates have been done in the past in Belgium and
the Netherlands [24,30,31], but were not necessary for the
present study.
We sampled a fraction of almost 25% in a six month
period from June 1st until November 30th 2007. This
amounted to 6928 death cases, approximately 12% of all
deaths in 2007 (percentages based on the mortality rate of
Flemish deaths for 2006, the most recent reference year
for which mortality statistics were available). The sample
size and proportion are significantly larger than in the pre-
vious Flemish ELD studies [13,14,19], ensuring the
greater overall statistical power of the results. The sample
size necessary to estimate accurately the incidence rates
with a confidence level of 95% was calculated based on
the response level of the previous Flemish ELD studies in
1998 (49%) in 2001 (59%) [32].
The sample is proportioned for month of death and prov-
ince of death (Flanders consists of five provinces). From
the previous ELD studies we know that ELDs occur more
frequently among patients with a certain cause of death
[13,14]. We therefore adopted disproportionate sampling
of deaths to include more patients with a cause of death
known to have a higher likelihood of one or more ELDs.
This should result in more cases in which an ELD pre-
ceded death, and should thus further increase the statisti-
cal power and reliability of the incidence estimates and
descriptions, even for the less-prevalent ELDs. According
to the underlying cause of death on the death certificates
and the corresponding probability of an end-of-life deci-
sion being made (derived from the data of the Flemish
2001 ELD study) deaths are grouped into one of four
strata and sampled disproportionately (see Table 1).Page 3 of 10
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years of age at death) may differ from that in adults, we
also integrated a fifth stratum. As there are relatively few
deaths of minors annually, all deaths of minors in the
period June-November 2007 are sampled to guarantee
reliable incidence estimates for deaths in this age category.
Questionnaire (see additional file 1)
In developing the questionnaire, attention was paid to
issues of length, difficulty, clarity, term ambiguity and
similarity of content to questionnaires in previous ELD
studies. We developed a questionnaire which drew on
those of the previous studies in Belgium, the Netherlands
and other European countries, the first of which had been
developed for the 1990 Dutch survey on ELDs [9]. We
used the same set of key questions to ask about the medi-
cal decisions that were made at the end of life, thereby
making possible incidence estimates comparable to those
in earlier studies. Secondary questions regarding the deci-
sion-making process preceding an ELD, treatments and
care provided, pain and other symptoms present in the
last 24 hours before death and the perceived quality of
dying were altered or added. The questionnaire was thor-
oughly analysed and tested by several physicians to cor-
rect for any imperfections or ambiguities. Its length was
limited to five pages and the difficulty of the questions
was kept as low as possible, bearing in mind the complex-
ity of the research subject. The original Flemish version of
the questionnaire is provided as additional file 1 to this
manuscript.
There are four sections to the questionnaire. In the first,
general section the physicians fill in their occupation
(general practitioner or specialist), whether they had con-
tact with the patient before his or her death and whether
or not the death was sudden and unexpected. The other
sections are to be completed only if the treating physician
had contact with the patient prior to death and death was
not sudden and completely unexpected. The second sec-
tion asks key questions concerning the medical decisions
that were made at the end of the patient's life. Terms such
as 'euthanasia' or 'physician-assisted suicide' are not used,
as they are emotionally charged and subject to ambiguous
and multidimensional definition. Instead, the types of
ELDs are more validly determined by establishing (1)
what act the physician initiated, (2) to which extent the
physician intended life-shortening when initiating the act,
and (3) if there had been an explicit request from the
patient to initiate the act. Figure 1 shows how a classifica-
tion of ELDs is derived from the answers to the key ques-
tions. If more than one ELD was made, the decision with
the most explicit intention of hastening death is given pri-
ority in the classification. And if there was more than one
act with a similar intention to hasten death, the adminis-
tering of drugs is chosen over the withholding or with-
drawal of treatment. In the third section physicians can
note the likely degree to which life was actually shortened
and some characteristics of the decision-making process.
We included additional questions also posed in the 2005
Dutch ELD study in this section: one about whether or not
euthanasia cases were reported, as is required by the
Euthanasia Law, and if not why they were not reported
Table 1: Four strata for disproportionate stratification based on cause of death*
Stratum 0
Cause of death implies that an ELD is certain
Included causes of death: euthanasia**.
Every death in this stratum is selected for the survey.
Stratum 1
Cause of death implies that an ELD is probable
Included causes of death: neoplasms (ICD-10 codes: C, D00–D48).
One out of every two deaths in this stratum is selected for the survey.
Stratum 2
Cause of death implies that an ELD is possible
Included causes of death: endocrine, nutritional and metabolic diseases; mental and behavioural disorders; diseases of the nervous system; diseases 
of the respiratory system; diseases of the digestive system; diseases of the genitourinary system (ICD-10 codes: E, F, G, J, K, N).
One out of every four deaths in this stratum is selected for the survey.
Stratum 3
Cause of death implies that an ELD is improbable
All remaining causes of death are included in this stratum (ICD-10 codes: A, D50–D99, H, I, L, M, Q, R, S, T, U, V, Y).
One out of every eight deaths in this stratum is selected for the survey.
* Causes of death were grouped into strata based on the probability of an ELD as observed in the Flemish part of the EURELD six nations study 
(2001) [14].
** Although there is no box to specify euthanasia in the death certificate, it is occasionally written down by the certifying physician in the section 
'immediate cause of death'.Page 4 of 10
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describe their act. The fourth section comprises questions
about the characteristics of care and treatment provided at
the end of the patient's life, the symptoms observed in the
last 24 hours as well as the perceived quality of the
patient's death. Finally we integrated a set of questions in
this section about palliative or terminal sedation (defined
as continuous deep sedation until death). In addition to
the types of drugs used for the sedation, the length of the
sedation, and the withdrawal of food and fluids, the ques-
tionnaire asks about the presence of an explicit request by
the patient or the family, possible alternatives to sedation
and whether a life-shortening intention was present.
Thus, the questionnaire can pursue the paramount ques-
tion of whether sedation is performed as a treatment deci-
sion with no life-shortening intention whatsoever or as an
ELD or even as an alternative to euthanasia, as suggested
in the literature [7,33-35] and in recent research [20].
Mailing procedure and anonymity
Safeguarding the anonymity of physicians and patients is
not only necessary for obvious ethical reasons but also for
judicial reasons. Some life-ending acts can be deemed
unacceptable by the Belgian criminal law and if anonym-
ity were not guaranteed physicians could risk criminal
prosecution for end-of-life decisions reported in this
study. Moreover, the response rate to the questionnaire as
well as the reliability of the answers will only improve if
physicians feel safe enough to answer. Therefore a rigor-
ous procedure was implemented to guarantee that no
completed questionnaire could be linked to a particular
patient or physician and that both patients and physicians
remained anonymous. This procedure has been used in
past studies on ELDs, and has proved effective
[9,10,13,14,20]. To meet the requirement of anonymity,
the different stages of the survey i.e. the sampling and
mailing, receiving and processing of the questionnaires
are spatially separated. Each stage is performed by differ-
ent persons. Four parties are involved in the survey, each
with specific functions. For a schematic overview of the
procedure, see Figure 2.
1. Flemish Agency for Care and Health (of the Flemish Ministry for 
Welfare, Public Health and Family)
The Flemish Agency for Care and Health, the official
department for processing death certificates, is responsi-
Questions to determine end-of-life decisionsFigure 1
Questions to determine end-of-life decisions.
Did you or another physician perform one or more of the following acts (or ensure that one of them was
performed), taking into account the probability or certainty that this act would hasten the end of the patient’s life?
                a. withholding treatment? O yes non-treatment decision
O no
                b. withdrawing treatment? O yes non-treatment decision
O no
                c. intensifying the alleviation of pain and/or O yes alleviation of pain and symptoms
                    symptoms by using a drug? O no
Was hastening the end of life partly the intention of O yes alleviation of pain and symptoms
intensifying pain and symptom alleviation? O no
Was death the consequence of one or more of the following acts, which you or another physician decided to
perform with the explicit intention of hastening the end of life?
                a. withholding treatment? O yes non-treatment decision
O no
                b. withdrawing treatment? O yes non-treatment decision
O no
Was the death the consequence of the use of a drug O yes physician-assisted death
prescribed, supplied, or administered by you or another O no
physician with the explicit intention of hastening the 
end of life (or of enabling the patient to end his or her 
own life)?
If yes, who administered the drug(s)? O the patient physician-assisted suicide




Was the decision concerning the last-mentioned act O yes, after an oral request
made after an explicit request of the patient? O yes, after a written request
O yes, after an oral and written request
O no life-ending act w ithout patient's explicit requestPage 5 of 10
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of the sample database, and the mailing of the question-
naires. Each case is ascribed a unique sample number
which is derived from the death certificate number using
a fixed algorithm. These sample numbers are used at the
end of the study to link the questionnaires to the patients'
socio-demographic and morbidity data, derived from the
death certificates, in a database provided by the Flemish
Agency for Care and Health (cfr. infra). An accompanying
letter is included with the questionnaire providing the
physician with enough patient characteristics derived
from the death certificates to identify the patient (i.e. sex,
date of birth, date of death, and municipality of death).
The researchers do not have access to the sample database
as it contains identifying information of the patients and
physicians.
2. Physicians
After identifying the patient by the patient characteristics
in the accompanying letter, the physicians can fill out the
questionnaires. They are advised to destroy the accompa-
nying letter afterwards. No combination of answers given
in the questionnaires can lead to identification of the
patient or of the physician.
In some cases, the certifying physician was not the treating
physician for the patient in question. In such cases the
physician is given a directive to transmit the questionnaire
to the treating physician. If the identity of the treating
physician is not known the case in question is discarded
as being impossible to study. Also, some physicians no
longer work at the hospital or practice where the patient
died and can therefore not identify the patient or do not
have access to the patient file. These cases are also
removed from the sample.
Schematic overview of the mailing and anonymity procedureFigure 2
Schematic overview of the mailing and anonymity procedure.Page 6 of 10
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The completed questionnaires are not returned to the
Flemish Agency for Care and Health or to the researchers
but instead to a sworn lawyer who is bound to profes-
sional confidentiality. The lawyer safeguards the anonym-
ity of the questionnaires received by removing any
possible identifying information from them such as notes,
stamps and signatures. He also removes the sample num-
bers and reports them to the Flemish Agency for Care and
Health. These cases are subsequently deleted from the
sample database so that the certifying physician does not
receive further reminders regarding this particular death.
As removing the sample numbers from the questionnaires
would make it impossible to link them to the correspond-
ing patient's socio-demographic and morbidity data at the
end of the study, the lawyer ascribes a new number to
every questionnaire and keeps a database in which the
original sample numbers and the corresponding numbers
are linked to one another.
The lawyer keeps the received questionnaires until the end
of the survey. Afterwards, the Flemish Agency for Care and
Health transmits the database of the patients' socio-demo-
graphic and morbidity characteristics to the lawyer. The
lawyer links the cases in this database to their correspond-
ing new numbers via the original sample numbers and
then deletes the original sample numbers. When these
sample numbers (derived from the death certificates) are
deleted, the information in the database of patient charac-
teristics and the information in the questionnaires can no
longer be traced back to the corresponding death certifi-
cates.
4. Research group
After this complex procedure, the information in the data-
base and questionnaires is strictly anonymous: the
replacement of sample numbers by new numbers cuts the
link between questionnaires and death certificates and
neither the combination of patient characteristics nor the
information provided in the questionnaires can lead to
the identification of patients or physicians. The lawyer can
thus transmit the questionnaires and the database with
patient characteristics to the researchers, who combine the
data from both (using the new numbers) into one data-
base for analysis.
Total Design Method (TDM)
All efforts to attain a representative sample of deaths are
ineffective if the response rate does not reach a minimal
level, therefore some measures are taken to achieve this.
We followed some prescriptions from Don A. Dillman's
Total Design Method (TDM) for mail surveys [36]. Firstly,
we established an intensive follow-up mailing. After the
questionnaire is sent out, the physician receives a maxi-
mum of three reminders at an interval of 14 days until the
questionnaire is returned. In the second reminder a new
copy of the questionnaire is included, thus anticipating
the possibility of the physician having lost the original.
The TDM is based on the costs-benefits analysis of social
action; in a social context a person only acts if there are
advantages in that action. Given this principle, the proba-
bility of participating in a study will be greater if the study
succeeds in keeping the costs (i.e. disadvantages, efforts,
time) of participation as low as possible while at the same
time maximising the gains for the respondent [36]. To
minimise the costs of participation, the questionnaire was
kept as short as possible, and the difficulty-level of the
questions and answer options as low as possible consider-
ing the complexity of the study subject. A maximum of
five death cases per physician was decided on to limit
responder fatigue. A stamped return envelope was
included with every questionnaire sent out. We feel that
guaranteeing the anonymity of physicians and patients is
also an important measure in minimising the potential
costs of participation. To maximise the gains for the phy-
sicians, we stress the importance of the study for the med-
ical field, as the results can contribute to better and more
effective policies on end-of-life decisions in Belgium. Par-
ticipation can thus ultimately result in better conditions
for physicians to work in, as well as for patients at the end
of their lives. We also deem it important to communicate
the results of the study to the participants. All participat-
ing physicians are assured of an invitation to a seminar on
the study after the data collection. As an extra incentive, a
valuable artwork will be awarded to a randomly chosen
participating physician. Due to the large number of partic-
ipating physicians, the funds are not sufficient to reward
every individual physician financially.
Additionally to the involvement of the Vrije Universiteit
Brussel and Ghent University in conducting the study,
representatives of two other Flemish universities, the
Katholieke Universiteit Leuven and Universiteit Antwer-
pen, and the Scientific Institute of Public Health support
the study to increase its visibility. Also, the positive recom-
mendation of the Belgian National Disciplinary Board of
Physicians (cfr. infra) is mentioned in the accompanying
letter.
Non-response survey
After the data collection a one-page questionnaire is sent
to all non-responding physicians, asking about their rea-
sons for non-response. Besides providing interesting
information on non-response in general, these reasons
can warrant the removal of some cases from the sample
because of the physician's inability to fill out the ques-
tionnaire (e.g. the patient cannot be identified with the
information provided, the physician no longer has accessPage 7 of 10
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attending physician and can not identify him or her, or
the physician never received the questionnaire).
Data analysis
The researchers will prepare an SPSS 16.0 (SPSS Inc.) data-
base with coding scheme for a certified data management
company which will enter the data. Range and skip checks
will prevent key-punching errors, and the data quality will
further be improved partly via double data-entry and
partly through extensive random sample checks. The
researchers will perform data cleaning via SPSS syntax
operations.
The data will be weighted to correct for the disproportion-
ate stratification of underlying causes of death and the
deaths of minors. The influence of non-response on the
representativity of the data will subsequently be checked
and weighted through a comparison of proportionality of
underlying causes of death and other patient characteris-
tics (i.e. sex, age, educational level, marital status, living
situation, province of residence, month of death and place
of death) between deaths where responses have been
received and deaths within the general population in
2007.
Data will be analysed with descriptive statistics (valid per-
centages and 95% confidence intervals), as well as bi- and
multivariate association statistics using SPSS version 16.0.
Recommendations
Positive recommendations for the anonymity procedure
and study protocol were obtained from the Ethical Review
Board of the University Hospital of the Vrije Universiteit
Brussel, the Ethics Committee of the University Hospital
of Ghent University, the Belgian National Disciplinary
Board of Physicians and the Belgian Federal Privacy Com-
mission.
Discussion
The 2007 Flemish ELD study aims to produce representa-
tive incidence estimates of end-of-life decisions in Flan-
ders and to describe their characteristics as well as the
circumstances under which they occur. A summary of the
key characteristics of the study design is shown in Table 2.
The four methodological challenges formulated at the
outset of this article were addressed: (1) we opted for a ret-
rospective study design based on death certificates, as this
design provides the best chances of obtaining reliable
incidence estimates of ELDs and their characteristics from
a large and representative sample of deaths. Moreover, the
disproportionate stratification based on the likelihood of
an ELD preceding death further increases the statistical
power of the results (2) comparability of the data to ear-
lier studies is ensured by using the same set of key ques-
tions in the questionnaire, and by keeping the main
characteristics of the study design constant (3) a rigorous
procedure involving a lawyer as intermediary between
physicians and researchers is employed to guarantee the
anonymity of physicians and patients and (4) we use sev-
eral measures from the Total Design Method to obtain a
satisfactory response rate.
The study has some strengths as well as weaknesses related
to the use of death certificates and the study design in gen-
eral.
Strengths
Most studies in end-of-life care research are limited with
regard to sample size, care settings or illness types. This
impedes the chances of obtaining representative popula-
tion data in end-of-life care research. For example, one
study examined end-of-life practices in a sample of dying
patients but was set only in intensive care units [16].
Using death certificates on the other hand facilitates the
obtaining of robust data for the entire population, as a
large sample of deaths can be drawn across care settings
including all causes of death [28,37]. And, because of its
nationwide scope, this study design is most suitable for
international comparative research, as the EURELD six
nations study has shown [14]. Also, the retrospective
nature of the study design does not encounter the prob-
lems of patient burden, attrition or non-response of the
sickest patients found in prospective study designs
[28,29], and it does not run the risk of influencing end-of-
life practices, which is a realistic possibility in prospective
studies.
Because all deaths must be reported to the proper govern-
ment authorities, death certificates also allow the use of
the death as the unit of measurement, providing a clear
denominator for reliable estimation of the incidence of
ELDs [28]. The reliability of these estimates is not guaran-
Table 2: Summary of the study design
DEATH CERTIFICATE SURVEY
3 large sample of deaths
3 nationwide (over care settings and causes of death)
3 stratified disproportionately based on cause of death
QUESTIONNAIRE
3 short and validated questionnaire
3 key questions of ELDs identical to those in earlier studies
3 emotionally charged terms absent in key questions
MAILING PROCEDURE
3 guarantee of anonymity for physicians and patients
3 response-increasing measures
3 intensive follow-up mailingPage 8 of 10
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by a representative sample of physicians [11,12,18], as the
unit of measurement in these studies is the physician and
the number of deaths preceded by an ELD is estimated on
the basis of physician characteristics. Moreover, in con-
trast to the death certificate design, physicians in these
studies are not guaranteed to have attended a death.
Using death certificates also facilitates the anonymous
linking of patient characteristics to the information pro-
vided in the questionnaires, allowing the study of associ-
ations between socio-demographic and morbidity
characteristics of the patient on the one hand, and end-of-
life decision making and provided care at the end of life
on the other hand [38].
Another strength of the present study is that, whereas in
other end-of-life research physicians can be inadvertently
selected on the basis of their interest in or attitudes
towards end-of-life practices, the use of death certificates
excludes the possibility of a biased selection of physicians.
Weaknesses
The physician signing the death certificate is occasionally
not the patient's treating physician, and therefore is not in
a position to fill out the questionnaire. Despite the direc-
tive to transmit the questionnaire to the treating physi-
cian, some cases are impossible to study as the treating
physician cannot be identified. In some instances not
even the identity of the patient can be retrieved because
the treating physician no longer has access to the patient
file.
Because death certificates have to be processed by the
proper authorities before they can be made available for
research, there can be a considerable delay between the
patient's death and the study of that death [37]. The delay
in our study has reached as much as four months (there is
variation across countries, ranging from two to six
months). We can therefore not exclude some influence of
recall bias. To address this issue, we encourage physicians
to fill in their questionnaires using the patient files, which
are mostly readily at their disposal.
Given the death as the unit of measurement and the large
number of deaths studied, one physician can receive sev-
eral questionnaires. Despite a maximum of five cases for
each physician, responder fatigue and diminishing
response rates can result.
A structured and semi-closed questionnaire can often
overlook the intricacies of certain end-of-life decisions.
Moreover, the questionnaire used in this study has, for
reasons of response, been limited in length and time-con-
suming questions have been left out. There is a risk that in
some cases vital information can be missed. To counter
this problem, a section is provided at the end of the ques-
tionnaire in which the physician can comment or elabo-
rate on the answers given.
Opportunities for future research
The present study is the third in a series of death certificate
studies in Belgium. Keeping the study design and the
questionnaire constant creates the opportunity for future
studies to build on the comparable data obtained in the
past and to identify accurately developments in the field
of ELDs. The study design can be applied to research in
other countries, so that data can be produced for interna-
tional comparative research. Comparable data are already
available in Belgium, the Netherlands, Italy, Switzerland,
Denmark and Sweden [8-10,13-15,19,20]. Furthermore,
the use of death certificates in end-of-life care research
need not be limited to ELDs; they can also be applied in
retrospective research on other issues in this field [37].
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